Gadobutrol (Gadovist, BAY86-4875)
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Carotid Stenosis
Conditions
Carotid Stenosis
Trial Timeline
May 12, 2011 โ May 28, 2014
NCT ID
NCT01344447About Gadobutrol (Gadovist, BAY86-4875)
Gadobutrol (Gadovist, BAY86-4875) is a phase 3 stage product being developed by Bayer for Carotid Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01344447. Target conditions include Carotid Stenosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01660841 | Phase 3 | Completed |
| NCT01344447 | Phase 3 | Completed |
| NCT01344460 | Phase 3 | Completed |
| NCT01095081 | Pre-clinical | Completed |
| NCT00905879 | Pre-clinical | Completed |
| NCT00874640 | Pre-clinical | Completed |
| NCT00828737 | Approved | Completed |
Competing Products
9 competing products in Carotid Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abciximab | Eli Lilly | Phase 1/2 | 41 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| simvastatin + placebo | Merck | Pre-clinical | 23 |
| Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin | Merck | Phase 2 | 52 |
| Evolocumab | Amgen | Approved | 84 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Rimonabant + Placebo (for Rimonabant) | Sanofi | Phase 3 | 76 |